An evaluation of efficacy of prophylaxis drugs for acute mountain sickness

The efficacy of anti-AMS drugs, a randomized controlled clinical trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-12001952

Enrollment

Unknown

Registered

2012-02-17

Start date

2012-02-15

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute mountain sickness

Interventions

1:Rhodiola

2:Gaoyuankang

3:Ginkgo biloba

4:Acetazolamide

5:Placebo

Eligibility

Sex/Gender

All

Age

17 Years to 21 Years

Inclusion criteria

Inclusion criteria: 1. permanent residence =3500m.

Exclusion criteria

Exclusion criteria: (1) Obesity; (2) Lung, heart dysfunction; (3) Liver, kidney dysfunction; (4) Hypertension; (5) Anemia, coagulation disorder; (6) Allergy to sulfonamides; (7) Taking methazolamide or acetazolamide or any drugs used to prevent acute mountain sickness within one week before the initiation of the trial.

Design outcomes

Primary

Measure	Time frame
acute mountain sicknes;	—

Secondary

Measure	Time frame
Arterial oxygen saturation;Blood pressure;Respiratory rate;Heart rate;	—

Countries

China

Contacts

Public ContactWenjing Luo

luowenj@fmmu.edu.cn+86 029 84774863

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026